Supplementary Figures 1-3 from Oleandrin-mediated inhibition of human tumor cell proliferation: Importance of Na,K-ATPase α subunits as drug targets

Supplementary Figures 1-3 from Oleandrin-mediated inhibition of human tumor cell proliferation: Importance of Na,K-ATPase α subunits as drug target

Supplementary Data from The COX2 Effector Microsomal PGE2 Synthase 1 is a Regulator of Immunosuppression in Cutaneous Melanoma

Supplementary methods and materials and figure legends</p

Supplementary Data from The COX2 Effector Microsomal PGE2 Synthase 1 is a Regulator of Immunosuppression in Cutaneous Melanoma

Supplementary Table 1. Association between OS/RFS and expression group of mPGES1 and CD8 in stage III melanoma.</p

Supplementary Data from The COX2 Effector Microsomal PGE2 Synthase 1 is a Regulator of Immunosuppression in Cutaneous Melanoma

Supplementary Figure 1. Gating strategies for flow cytometry data analysis. Supplementary Figure 2. Co-staining of mPGES1 and S100 in human melanoma tissues. Supplementary Figure 3. Chemokines/cytokines related to COX2 or mPGES1 in melanoma. Supplementary Figure 4. Effect of COX2 or mPGES1 inhibitors on surface expression of PD-L1. Supplementary Figure 5. Comparison of PGE2 level and cell viability in scramble, PTGES KO and PTGS1/PTGS2 double KO mouse melanoma cell lines. Supplementary Figure 6. Prognostic effect of mPGES1 in Stage IV melanoma. Supplementary Figure 7. Association between mPGES1 levels and response of anti-PD-1 therapy.</p

Supplementary figure from Activator Protein-1 Has an Essential Role in Pancreatic Cancer Cells and Is Regulated by a Novel Akt-Mediated Mechanism

Supplemental Figure 1</p

Supplemental Figure Legends from Activator Protein-1 Has an Essential Role in Pancreatic Cancer Cells and Is Regulated by a Novel Akt-Mediated Mechanism

Supplementary Figure. 1A. Nuclear extracts (N.E.) from various serum-starved pancreatic cancer cell lines were probed for NF-κBbinding activity. Also included were serum-starved Panc-28 cells after stimulation by IL-1. Supershift assays were performed with unstimulated Panc-28 cell extracts using anti-p65/NFκB and nonspecific (IgG) antibodies. Supplementary Figure. 1B Whole-cell extracts were prepared from untreated or TNF-treated cells and then incubated with anti- JNK1/2 antibodies. Immune complexes were washed several times with a lysis buffer and assayed for JNK kinase activity with 2 μg of GST-c-Jun (amino acids 1-79) used as substrate. Assay mixtures, which included 0.2 mM [γ-32P] ATP and 10 mM MgCl2, were incubated for 5 min at 30 {degree sign}C, at which point the reactions were terminated by the addition of a sodium dodecyl sulfate sample buffer. Radiolabeled GST- c-Jun bands were detected by autoradiography. Serum-starved Panc-28 cells were treated with or without the JNK inhibitor SP600125 for 2 h. Whole-cell extracts were probed by Western blotting for c-Jun and phospho-c-Jun (Ser63). Supplementary Figure. 1C. A collagenase/luciferase reporter gene with (-73 Col/luc) or without (-60 Col/luc) an AP-1-binding site was cotransfected with the indicated constructs into c-Jun-/- MEFs stably expressing the pMX vector, c- Jun-TA or c-Jun SAA/TA. Sixteen to twenty four hours after transfection, cells were serum-starved overnight and either harvested right away or stimulated with PDGF-BB (10 ng/ml). After PDGF treatment (24 h) cells were lysed and protein extracts assayed for luciferase activity. Each data point was obtained in triplicate and used to calculate the averages and standard deviations.</p

Supplementary Table from Precision Combination Therapies Based on Recurrent Oncogenic Coalterations

Supplementary Table from Precision Combination Therapies Based on Recurrent Oncogenic Coalteration

Supplementary Table from Precision Combination Therapies Based on Recurrent Oncogenic Coalterations

Supplementary Table from Precision Combination Therapies Based on Recurrent Oncogenic Coalteration

Supplementary Table from Precision Combination Therapies Based on Recurrent Oncogenic Coalterations

Supplementary Table from Precision Combination Therapies Based on Recurrent Oncogenic Coalteration

Supplementary Table from Precision Combination Therapies Based on Recurrent Oncogenic Coalterations

Supplementary Table from Precision Combination Therapies Based on Recurrent Oncogenic Coalteration